TRAW earnings analysis
What we found in TRAW's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Traws reported $0 of Q2 2026 revenue and diluted EPS of negative $0.16, with no segment, margin, cash-flow, or balance-sheet figures available in the provided filing extract. Management maintained its MHRA resubmission target for the end of Q3 2026 and FDA clinical-hold resolution target for the end of 2026. The newly disclosed Nasdaq deficiencies—including a bid price below $1.00 for at least 30 consecutive business days and potential exposure to a $5 million MVLS requirement—materially increase financing and delisting risk.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Zero Revenue; Diluted EPS Loss
- Q2 2026 revenue was $0 and diluted EPS was negative $0.16, confirming the company remains pre-commercial.
- MHRA Resubmission Target Maintained
- Management maintained its target to resubmit the revised toxicology package to the MHRA by the end of Q3 2026.
- FDA Hold Resolution Target
- The company continues to target resolution of the FDA clinical hold by the end of 2026.
- Disclosure Controls Effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Nasdaq Minimum-Bid Deficiency
- On July 29, 2026, Nasdaq notified the company that its closing bid price had remained below $1.00 for at least 30 consecutive business days. The company has until January 25, 2027 to regain compliance, subject to potential extensions.
- Potential $5 Million MVLS Rule
- A potential Nasdaq continued-listing rule would require minimum market value of listed securities of $5 million; if effective, companies below that level for 30 consecutive business days could face immediate suspension and delisting without a cure period.
- Delisting and Reverse-Split Risk
- The company states that failure to regain compliance could lead to delisting, reducing liquidity and making it more difficult to raise capital. A reverse stock split may be required, but the filing states it may not maintain a share price above the $1.00 requirement.
- Pre-Revenue Funding Dependence
- The company reported $0 of Q2 2026 revenue and a diluted EPS loss of $0.16, leaving future funding dependent on capital markets and successful regulatory progress.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.16
What they said about what is next.
No quantitative revenue or EPS guidance was provided. Management maintained its outlook to resubmit the revised toxicology package to the MHRA by the end of Q3 2026 and to resolve the FDA clinical hold by the end of 2026.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 15, 2026
- Traws Pharma's Q4 2026 results showed no revenue, resulting in a net loss of $7.1 million compared to a net income of $21.5 million in Q4 2025. Operating expenses increased primarily due to higher R&D costs related to…
- 10-K · April 30, 2026
- Traws Pharma reported disappointing financial results with an EPS of -$0.71, missing estimates of -$0.69, and did not report revenue for Q4 2025. The company successfully raised approximately $10 million from a private…
- 10-K · April 15, 2026
- Traws Pharma is a clinical-stage biopharmaceutical company focused on respiratory viral diseases and oncology with four clinical programs (tivoxavir marboxil, ratutrelvir, narazaciclib and rigosertib). The company…
- 10-Q · November 13, 2025
- Traws Pharma reported a third-quarter net loss of $3,962,000 (‑$0.34 per share) versus a loss of $8,475,000 (‑$1.49) in Q3 2024, driven by lower operating expenses but with revenue effectively $0 for the quarter (prior…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing TRAW makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever